Skip to content
Peptigraph home

Semaglutide for Liver Health: What the Evidence Shows

What human and animal studies show about Semaglutide for liver health, how strong that evidence is, and what is still unproven.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureGLP-1 agonistUpdated
Strongest evidence
Human RCT
Human studies
305
PubMed records, our ledger
Animal studies
59
PubMed records, our ledger
Studies we summarised
2
with an outcome for liver health

Evidence for liver health

Each row is an outcome related to liver health from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.

Semaglutide for liver health: outcomes in published studies
OutcomeResultStudy typeSource
Steatohepatitis resolutionSteatohepatitis resolved without worsening fibrosis in 62.9% on semaglutide vs 34.3% on placebo.Human RCTn = 1197The New England journal of medicine 2025, PMID 40305708
Fibrosis reductionLiver fibrosis was reduced without worsening steatohepatitis in 36.8% on semaglutide vs 22.4% on placebo.Human RCTn = 1197The New England journal of medicine 2025, PMID 40305708
NASH resolutionNASH resolved without worsening fibrosis in 59% at 0.4 mg vs 17% on placebo.Human RCTn = 320The New England journal of medicine 2021, PMID 33185364
Fibrosis stage improvementFibrosis improved in 43% at 0.4 mg vs 33% on placebo, not a significant difference (P = 0.48).Human RCTn = 320The New England journal of medicine 2021, PMID 33185364

PubMed records for Semaglutide and liver health: 305 human, 59 animal (search counts, not studies we reviewed). Grades follow our .

How strong is it?

Strongest evidence:Human RCT evidence, 4 of 4The New England journal of medicine 2025, PMID 40305708

A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.

Fatty liver, MASH and where semaglutide fits

MedlinePlus says steatotic liver disease, formerly called fatty liver disease, happens when too much fat builds up in the liver.[3]

The Wegovy label has a MASH indication, for noncirrhotic disease with moderate to advanced fibrosis, and notes it was granted under accelerated approval based on improvement of MASH and fibrosis.[4]

The label's MASH indication is for adults with stages F2 to F3 fibrosis.[4]

What the liver trials found

In the phase 3 MASH trial, steatohepatitis resolved without worsening fibrosis in 62.9% on semaglutide against 34.3% on placebo.[1]

Reduced fibrosis without worsening steatohepatitis was seen in 36.8% on semaglutide against 22.4% on placebo.[1]

The earlier phase 2 trial showed NASH resolution in 59% at the highest dose against 17% on placebo, yet fibrosis improvement was not significantly different there.[2]

Safety to know

In the phase 2 liver trial nausea, constipation and vomiting were more common at the top dose than on placebo, and it reported malignant neoplasms in 3 treated patients and none on placebo.[2]

Other peptides people research for liver health

All peptides for liver health, compared

Common questions

Does Semaglutide help with liver health?

The strongest study we summarise for liver health is human rct evidence, across 2 studies with an outcome for liver health. A trial result is not an approval; see the legal status.

Is Semaglutide approved for liver health?

Semaglutide is FDA approved (Ozempic, Wegovy, Rybelsus). Which conditions that approval covers is set by the label; use for anything else is off-label.

What is the best peptide for liver health?

There is no single answer. Our liver health overview compares each candidate by evidence grade and legal status rather than by popularity.

Is semaglutide approved for fatty liver?

Wegovy is approved, under accelerated approval, for noncirrhotic MASH with moderate to advanced fibrosis in adults.[4]

Does semaglutide reduce liver fat?

The cached trials report MASH histology rather than liver fat percentage; the phase 3 result is resolution of steatohepatitis in 62.9% on semaglutide versus 34.3% on placebo.[1]

More on Semaglutide

Sources

  1. 1Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.The New England journal of medicine · 2025PMID 40305708Accessed 2 Oct 2026
  2. 2A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.The New England journal of medicine · 2021PMID 33185364Accessed 2 Oct 2026
  3. 3medlineplus.gov pagemedlineplus.gov · web pagemedlineplus.gov
  4. 4WEGOVY prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026

Found an error? Report a correction.